A Clinical Trial of Thread-embedding Therapy at Acupuncture Point for Simple Obesity
A Clinical Trial of Acupoint Thread-embedding Therapy for Simple Obesity
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Miao Wang
- Phone Number: 9507 +86-64385700
- Email: wangmiao_126@126.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Institute of Digestive Diseases of Longhua Hospital affiliate to Shanghai University of Traditional Chinese Medicine
-
Contact:
- Guang Ji
- Phone Number: 9503 +86-64385700
- Email: jiliver@vip.sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with age from 18 to 60 years old;
- patients with BMI≥ 24, meanwhile waist more than 85 cm (for male) or 80 cm (for female);
- patients with diagnosed as central adiposity and/or Simple obesity according to the diagnosis criteria;
- patients who is willing to cooperate with the test treatment and signed informed consent.
Exclusion Criteria:
- Pregnant or lactating women;
- patients who Syncope after acupuncture;
- patients who present hypersensitivity reactions after acupoint-embedding therapy;
- patients with serious heart, liver, kidney, brain and other diseases;
- patients with severe primary diseases;
- patients with psychiatric diseases;
- patients who did not meet the criteria for the inclusion criteria while investigators find out during the trial;
- participants who did not complete dietary control and physical exercise as the protocol described.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: participants received treatment
100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial.
Each will receive Thread-embedding therapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change Body Weight
Time Frame: participants will receive Thread-embedding Therapy twice a week lasting for 16 weeks subsequently.8 times in all.
|
a 5 percent of loss of body weight will be judged as effective
|
participants will receive Thread-embedding Therapy twice a week lasting for 16 weeks subsequently.8 times in all.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effection on cholesterol
Time Frame: Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
a target examined by blood test, in order to compare the Lipid metabolism
|
Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
|
The effection on triglyceride
Time Frame: Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
a target examined by blood test, in order to compare the Lipid metabolism
|
Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
|
The effection on fasting blood glucose
Time Frame: Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
to compare the level of glucose in order to get the message of improvement of blood glucose disorder by our therapy.
|
Therapy is the same as mentioned above. Participants will take blood test at the beginning of the first week of the therapy, and at the end of the 16th week.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- shutcmidd
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.